The rs8192288 variant was also identified as a risk factor for BC patients carrying the GT, TT, and GTTT genotypes, particularly when combined with menopause, luminal A type, advanced tumor progression (stages III–IV), ki-67 ≥ 20%, ER-positive, nonresponsiveness to chemotherapy, and DM. This evidence concerns the gene ESR1 and neoplasm.